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Abstract
Background: Bone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore,
there are few studies concerning the natural history of bone metastasis in patients with HCC.
Patients and Methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for
211 deceased HCC patients with evidence of bone metastasis were statistically analyzed.
Results: The median age was 70 years; 172 patients were male (81.5%). The median overall survival was 19 months. The
median time to the onset of bone metastasis was 13 months (22.2% at HCC diagnosis); 64.9% patients had multiple bone
metastases. Spine was the most common site of bone metastasis (59.7%). Most of these lesions were osteolytic (82.4%);
88.5% of them were treated with zoledronic acid. At multivariate analysis, only the Child Score was significantly correlated
with a shorter time to diagnosis of bone metastases (p= 0.001, HR = 1.819). The median survival from bone metastasis was 7
months. At multivariate analysis, HCC etiology (p= 0.005), ECOG performance status (p= 0.002) and treatment with
bisphosphonate (p= 0.024) were associated with shorter survival after bone disease occurrence. The site of bone metastasis
but not the number of bone lesions was associated with the survival from first skeletal related event (SRE) (p= 0.021) and OS
(p= 0.001).
Conclusions: This study provides a significant improvement in the understanding the natural history of skeletal disease in
HCC patients. An early and appropriate management of these patients is dramatically needed in order to avoid subsequent
worsening of their quality of life.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most prevalent
cancer worldwide and the third leading cause of cancer-related
death, although its geographical distribution is heterogeneous with
the highest incidence in sub-Saharan Africa and Eastern Asia [1].
The choice of its therapy is related to the stage of the disease,
severity of the underlying liver disease, and clinical expertise.
Unfortunately, two thirds of patients are diagnosed at an advanced
stage, when prognosis is poor with 5-year survival rates of less than
20% [2].
HCC is less likely to develop distant metastases, even in the
inoperable stage, compared to other solid tumors with the lung as
the most common site of localization [3]. Although bone
involvement is reported as uncommon in HCC, its incidence has
significantly increased in the last decade due to the improvement
of overall survival of these patients [4,5]. One recent study
considering 342 HCC patients reported skeletal invasion in
approximately 25% of extrahepatic metastases [6].
Axial skeleton is the most frequent localization of bone
metastases with a prognostic correlation of the time between the
primary HCC occurrence and bone metastases detection [7].
They are mainly osteolytic resulting in significant morbidity and
reduced quality of life for patients from the associated skeletal-
related events (SRE; defined as pathological fracture, the need for
radiotherapy or surgery to bone, spinal cord compression, and
hypercalcemia) [8]. Radiotherapy is the most common SRE,
playing a role in bone pain palliation, mostly for patients whose
liver failure can be associated with a reduced patients’ opioid
tolerance. In most of cases, higher radiotherapy doses are required
due to the presence of soft tissue masses in addition to bone
involvement [9]. Indeed, few retrospective studies evaluated the
use of biphosphonates in HCC-bone metastases [4]. Low doses of
sorafenib have been associated to long term progression free
survival in some patients [10].
Finally, herein we report the results of the largest multicenter
study investigating the natural history (and their clinical manage-
ment) of bone metastases from HCC.
Patients and Methods
Ethics Statement
This multicentre retrospective observational study has been
approved by the Ethics Committee of the coordinator centre
(National Cancer Institute of Bari). According to our Ethics
Committee, a written consent was not needed. In fact, this is a
retrospective observational study considering only died patients
whose recruitment in the survey did not influenced their
treatment.
Study design
This retrospective, observational multicentre study aimed at
defining the natural history of HCC patients with bone metastasis
was conducted in 23 Italian hospital centres in which these
patients received diagnosis and treatment of disease from January
1993 to May 2013. Data were collected from HCC patients of all
ages who received standard treatments in accordance with each
own treating physician’s practice and were not included neither in
clinical trials nor experimental protocols. Moreover, patients had
at least one bone metastasis during the course of their disease and
died of HCC or HCC-related complications. In details, patients
were identified as having bone metastasis if two of the following
criteria were satisfied: physician reported bone metastasis; bone
metastasis identified by bone scan; record of radiotherapy to bone
as a palliative therapy; identification of bone metastasis by other
imaging assessment (e.g. standard x-rays, computed tomography
scans, or magnetic resonance imaging of the skeleton). Data were
collected throughout the disease course and during all cancer
treatments, including surgery, radiation therapy, locaregional
therapies, chemotherapy, and biological therapies. Variables
assessed included age, sex, aetiology, grading, Child score at
diagnosis, presence and type of locoregional treatment, the median
value of Alpha-fetoprotein (AFP) at diagnosis, number and sites of
bone metastasis, visceral metastases, ECOG performance status
(PS) at the moment of bone metastases diagnosis, time to
appearance of bone metastasis, times to first and subsequent
SREs (from diagnosis of bone metastasis), SRE types, survival after
bone metastases diagnosis and after first SRE, systemic therapy
with Sorafenib and type and time of bisphosphonate therapy.
Statistical analysis
Descriptive statistics were used for patient demographics and
incidence of SREs. All survival intervals were determined by the
Kaplan-Meier method. The differences in survival according to
clinical parameters or treatment were evaluated by the log-rank
test and described by the Kaplan–Meier method unless otherwise
specified. In the univariate model, all the clinical variables were
evaluated as predictors for shorter time to bone metastasis, shorter
time from bone metastases to SRE and shorter time from bone
metastases to death. Patients who did not have a recorded date for
a specific event were censored at the date of death. Finally, the
Cox proportional hazards model was applied to the multivariate
survival analysis. All the significant variables in the univariate
model were used to build the multivariate model of survival, and
median values were derived from whole-month values rather than
fractions. SPSS software (version 20.00; SPSS, Chicago, IL) was
used for statistical analysis. A p value,0.05 was considered
statistically significant.
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Results
Patient characteristics
We retrospectively enrolled 211 patients died from HCC with
bone metastasis. Of them, 172 patients were male (81.5%). The
median age was 70 years (SD +/29). Tumor etiology of HCC was
HBV related in 35/211 (16.5%) patients, HCV related in 110/211
(52.1%) patients, alcohol related in 20/211 (9.4%) patients and
other causes-related in 46/211 (21.8%) patients. The subgroup
Table 1. Baseline characteristics.
Baseline characteristics (Total N=211) Frequency (pts/total applicable) P (%)
Age
,70 Years 111/205 54.1
.70 Years 94/205 45.9
Gender
Male 172/211 81.5
Female 39/211 18.5
Aetiology
HBV-related 35/211 16.5
HCV-related 110/211 52.1
Alcohol-related cirrosi 20/211 9.4
Other 46/211 21.8
Grading
G1 28/98 28.6
G2 30/98 30.6
G3 40/98 40.8
Locoregional Treatment
No 149/211 70.6
Yes 62/211 29.4
Type of locoregional Treatment
Surgery 50/149 33.5
Interventional Radiology 89/149 66.5
Type of interventional Radiology
RFA 23/89 25.8
TACE 57/89 64.0
PEI 9/89 10.1
CHILD Score
A 133/191 69.8
B 42/191 22.0
C 16/191 8.4
Visceral Metastasis
Yes 151/211 71.6
No 60/211 28.4
AFP (cut-off value of 200 ng/mL at diagnosis)
,200 ng/ml 97/149 65.1
.200 ng/ml 52/149 34.9
AFP (median value at diagnosis)
,43 ng\ml 75/149 50.4
.43 ng/ml 74/149 49.6
Sorafenib Treatment
Yes 132/211 62.6
No 79/211 37.4
Abbreviations: n, number; pts, patients; HBV, Hepatitis B virus; HCV, Hepatitis C virus.
doi:10.1371/journal.pone.0105268.t001
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Table 2. Skeletal metastases.
Skeletal metastases (total n=211) Frequency (pts) Percentage (%)
ECOG PS (at time of Bone Metastasis)
0 51/194 26.3
1 78/194 40.2
2 50/194 25.8
3 15/194 7.7
Bone Metastasis at diagnosis
Yes (synchronous) 161/207 77.8
No (metachronous) 46/207 22.2
Bone Lesion Type
Osteolytic 169/205 82.4
Osteoblastic 16/205 7.8
Mixed 20/205 9.8
Number of Bone Metastasis
1 74/211 35.1
.1 137/211 64.9
Bone Metastasis Localization
Spine 126/211 59.7
Long Bones 41/211 19.4
Hip 74/211 35.1
Other Sites 61/211 28.9
Total SRE Number
0 84/211 39.9
1 127/211 60.1
2 40/211 18.9
3 6/211 2.8
First SRE Type
Pathological Fracture 31/127 24.4
Hypercalcemia 7/127 5.5
Spinal Cord Compression 12/127 9.4
Surgery to Bone 7\127 5.5
Radiation to Bone 70/127 55.1
Second SRE Type
Pathological Fracture 5/40 12.5
Hypercalcemia 6/40 15
Spinal Cord Compression 5/40 12.5
Surgery to Bone 5/40 12.5
Radiation to Bone 19/40 47.5
Third SRE Type
Pathological Fracture 0/6 0.0
Hypercalcemia 0/6 0.0
Spinal Cord Compression 0/6 0.0
Surgery to Bone 2/6 33.4
Radiation to Bone 4/6 66.6
Biphosphonate Treatment 105/211 49.7
Zoledronic Acid 93/105 88.5
Pamidronate 6/105 5.6
Other 7/105 6.6
doi:10.1371/journal.pone.0105268.t002
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with Child A was the largest (69.8%) patients, followed by the
subgroup with Child B (22.0%) and Child C (8.2%) patients. The
majority of patients (132/211; 62.6%) was treated with Sorafenib.
The remaining baseline characteristics as grading, presence and
type of locoregional treatment, presence of visceral metastases and
the median value of AFP at diagnosis were summarized in
Table 1.
Skeletal metastases
The ECOG PS at the moment of bone metastasis diagnosis was
0 for 51/194 patients (26.3%), 1 for 78/194 (40.2%), 2 for 50/194
(25.8%), 3 for 15/194 (7.7%) and unknown in 17 patients (8%).
One hundred and sixty one patients (77.8%) developed bone
metastasis after HCC diagnosis while 46 patients (22.2%) showed
bone metastasis at the time of HCC diagnosis; 137 of 211 patients
(64.9%) had multiple bone metastases and the remaining 74/211
Table 3. Predictive factors of onset of bone metastasis.
VARIABLES
MEDIAN TIME
(MONTHS)
p VALUE
(uni variate)
p VALUE
(multivariate)
HAZARD
RATIO (HR)
Age 0.604
,70 Years 12.0 (9.37–14.63)
.70 Years 16.0 (11.11–20.89)
Gender 0.807
Male 15.0 (11.77–18.24)
Female 12.0 (9.13–14.87)
Aetiology 0.715
HBV-related 12.0 (3.84–20.16)
HCV-related 14.0 (10.35–17.65)
Alcohol-related cirrhosis 15.0 (9.91–20.09)
Other 8.0 (5.37–10.63)
Grading 0.254
G1 24.0 (12.04–35.96)
G2 19.0 (12.11.25.90)
G3 10.0 (2.70–17.30)
Locoregional Treatment 0.360
No 14.0 (6.43–21.57)
Yes 14.0 (10.96–17.04)
Type of locoregional Treatment 0.037 0.988 0.994
Surgery 10.0 (8.41–11.59)
Interventional Radiology 17.0 (10.83–23.17)
Type of interventional Radiology 0.716
RFA 12.0 (2.61–21.39)
TACE 16.0 (10.35–21.65)
PEI 24.0 (11.53–36.47)
CHILD Score (at time of Bone Metastasis) 0.000 0.001 1.819
A 16.0 (10.40–21.60)
B 12.0 (9.32–14.68)
C 7.0 (4.93–9.07)
AFP (at diagnosis) 0.040 0.157 1.346
,43 ng\ml 17.0 (12.40–21.61)
.43 ng/ml 12.0 (8.47–15.53)
Bone Lesion Type 0.932
Osteolytic 14.0 (11.27–16.73)
Ostroblastic 16.0 (0.00–37.69)
Mixed 14.0 (3.82–24.18)
Abbreviations: CI, Confidence Interval; AFP, Alpha-fetoprotein; RFA, radiofrequency ablation; TACE, Transcatheter arterial chemoembolization; PEI, percutaneous ethanol
injection.
doi:10.1371/journal.pone.0105268.t003
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Table 4. Predictive factors of survival after bone metastases diagnosis.
VARIABLES
MEDIAN TIME
(MONTHS)
p VALUE
(uni variate)
p VALUE
(multivariate)
HAZARD
RATIO (HR)
Age 0.349
,70 Years 7.0 (5.83–8.18)
.70 Years 6.0 (4.35–7.65)
Gender 0.612
Male 6.0 (5.07–6.93)
Female 9.0 (7.33–10.67)
Aetiology 0.003 0.005 0.785
HBV-related 4.0 (2.18–5.82)
HCV-related 7.0 (5.61–8.39)
Alcohol-related cirrhosis 9.0 (4.73–13.27)
Other 8.0 (5.10–10.90)
Grading 0.866
G1 5.0 (3.38–6.62)
G2 6.0 (3.74–8.26)
G3 6.0 (4.04–7.96)
Locoregional Treatment 0.104
No 6.0 (4.93–7.07)
Yes 7.0 (5.97–8.03)
Type of locoregional Treatment 0.644
Surgery 8.0 (6.23–9.77)
Interventional Radiology 7.0 (5.72–8.28)
Type of interventional Radiology 0.366
RFA 7.0 (4.76–9.24)
TACE 7.0 (5.25–8.76)
PEI 7.0 (0.00–19.47)
CHILD Score
(at time of Bone Metastasis)
0.245
A 6.0 (4.95–7.06)
B 6.0 (3.93–8.07)
C 9.0 (5.08–12.92)
AFP (at diagnosis) 0.549
,43 ng\ml 7.0 (5.22–8.78)
.43 ng/ml 7.0 (5.93–8.07)
Visceral Metastasis 0.615
Yes 7.0 (4.14–9.86)
No 7.0 (6.03–7.97)
ECOG PS
(at time of Bone Metastasis)
0.002 0.002 1.341
0 8.0 (5.28–10.72)
1 8.0 (6.75–9.25)
2 6.0 (4.85–7.15)
3 4.0 (0.33–7.67)
Bone Lesion Type 0.608
Osteolytic 7.0 (6.05–7.95)
Ostroblastic 9.0 (7.70–10.30)
Mixed 7.0 (4.16–9.84)
Bone metastasis - Spine 0.006 0.075 1.339
No 9.0 (7.34–10.66)
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patients (35.1%) showed single lesion. Spine were the most
common site of bone metastasis (126/211; 59.7%) followed by hip
(74/211; 35.1%) and long bones (41/211; 19.4%) and are
consistent with previous reports. Osteolytic lesions (169/205;
82.4%) were far more prevalent in this group than the mixed ones
(20/205; 9.8%) and osteoblastic lesions (16/205; 7.8%). More than
half of the patients (127/211; 60.1%) experienced at least one SRE
while, two and three SREs have been reported in 18.9% (40/211)
and 2.8% (6/211) of patients, respectively (Table 2). Considering
only the first SRE, radiotherapy to bone is the most common (70/
127 patients; 55.1%), followed by pathologic fracture (31/127;
24.4%), spinal cord compression (12/127; 9.4%), surgery to bone
(7/127; 5.5%) and hypercalcemia (7/127; 5.5%) while for second
and third SRE, radiotherapy to bone also had the greater
incidence with 47.5% (19/40) and 66.6% (4/6) respectively.
Equally, considering all the different SREs, radiotherapy to bone is
the most common SRE (53.7% of all events), followed by
pathologic fracture (20.8%), spinal cord compression (9.8%),
surgery to bone (8%) and hypercalcemia (7.5%). Among the 211
patients with bone metastasis, 105/211 (49.7%) patients received
therapy with bisphosphonate: 93 patients (88.5%) were treated
with Zoledronic Acid, 6 patients (5.6%) with Pamidronate and 7
patients (6.6%) with other agents, respectively. No patient
developed osteonecrosis of the jaw (ONJ) (Table 2).
Predictive factors of onset of bone metastasis
The median time to the onset of bone metastasis was 13 months
(CI 95% 9.29–16.71 months). At univariate analysis (Table 3), the
median time to the onset of skeletal disease was significantly
shorter according to type of locoregional treatment (17 months for
interventional radiology vs. 10 months for surgery; CI 95% 8.412
11.58 and 10.82223.17, respectively; p= 0.037), Child Score (p,
0.001) and in patients with higher median AFP at diagnosis
(p= 0.040). At multivariate analysis, only the Child Score was
confirmed and independently correlated with a shorter time to
diagnosis of bone metastases (Table 3) (p= 0.001; HR: 1.819).
Predictive factors of survival after bone metastases
diagnosis
The median survival from the diagnosis of bone metastasis was
7 months (CI 95% 5.36–8.64 months). The univariate analysis,
reported in Table 4, demonstrates that the median survival after
diagnosis of bone metastases was significantly shorter according to
HCC etiology (4 months for HBV, 7 months for HCV, 9 months
for alcohol related and 8 months for other causes; CI 95% 2.182
5.81, 5.6128.38, 4.73213.26 and 5.10210.89 months, respec-
tively; p=0.003), ECOG PS (p=0.002), in patients with bone
metastasis localized to spine (p=0.006) and did not receive any
bisphosphonate treatment (p=0.001). Notably, at multivariate
analysis (Table 4) all these parameters were confirmed and
independently correlated with a shorter survival after bone disease
occurrence (p=0.005 with HR: 0.785 for etiology; p=0.002 with
HR: 1.341 for ECOG PS and p=0.024 with HR: 0.669 for
bisphosphonate treatment, respectively), excluding bone metastasis
to spine (p=0.075 with HR: 1.339).
Table 4. Cont.
VARIABLES
MEDIAN TIME
(MONTHS)
p VALUE
(uni variate)
p VALUE
(multivariate)
HAZARD
RATIO (HR)
Yes 6.0 (5.05–6.95)
Bone Metastasis - Long Bones 0.806
No 7.0 (6.11–7.89)
Yes 6.0 (2.48–9.52)
Bone Metastasis - Hip 0.428
No 7.0 (5.95–8.05)
Yes 6.0 (3.65–8.35)
Bone Metastasis - Other 0.941
No 7.0 (5.86–8.14)
Yes 7.0 (5.60–8.40)
First SRE Type 0.268
Pathologica Fracture 7.0 (3.90–10.10)
Hypercalcemia 9.0 (7.83–10–17)
Spinal Cord Compression 4.0 (0.00–9.09)
Surgery to Bone 9.0 (7.83–10.17)
Radiation to Bone 8.0 (6.55–9.45)
Biphosphonate Treatment 0.001 0.024 0.699
No 5.0 (3.58–6.42)
Yes 8.0 (6.78–9.23)
doi:10.1371/journal.pone.0105268.t004
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Table 5. Predictive factors of survival after HCC diagnosis.
VARIABLES
MEDIAN TIME
[MONTHS (95% C.I.)]
p VALUE
(univariate)
p VALUE
(multivariate)
HAZARD
RATIO (HR)
Age 0.818
,70 Years 18.0 (14.45–21.55)
.70 Years 20.0 (16.77–23.23)
Gender 0.589
Male 19.0 (14.06–23.94)
Female 19.0 (15.48–22.52)
Aetiology 0.077
HBV-related 15.0 (11.18–18.82)
HCV-related 24.0 (20.49–27.51)
Alcohol-related cirrhosis 16.0 (4.27–27.73)
Other 13.0 (9.00–17.01)
Grading 0.019 0.137 1.250
G1 27.0 (12.31–41.69)
G2 26.0 (22.50–29.50)
G3 12.0 (9.52–14.48)
Locoregional Treatment 0.000 0.000 0.265
No 8.0 (4.43–11.57)
Yes 24.0 (22.59–25.41)
Type of locoregional Treatment 0.594
Surgery 21.0 (16.36–25.64)
Interventional Radiology 24.0 (21.94–26.06)
Type of interventional Radiology 0.180
RFA 26.0 (17.03–34.97)
TACE 24.0 (20.62–27.38)
PEI 29.0 (12.37–45.63)
CHILD Score
(at time of Bone Metastasis)
0.001 0.049 1.572
A 21.0 (15.75–26.25)
B 18.0 (14.91–21.10)
C 16.0 (14.06–17.95)
AFP (at diagnosis) 0.419
,43 ng\ml 18.0 (12.03–23.97)
.43 ng/ml 19.0 (14.36–23.64)
Visceral Metastasis 0.091
Yes 24.0 (19.85–28.15)
No 18.0 (15.29–20.71)
Bone metastasis - Spine 0.018 0.001 2.281
No 21.0 (16.87–25.13)
Yes 19.0 (15.26–22.74)
Bone Metastasis - Long Bones 0.639
No 19.0 (15.65–22.35)
Yes 21.0 (9.59–32.41)
Bone Metastasis - Hip 0.840
No 23.0 (20.29–25.71)
Yes 15.0 (11.87–18.13)
Bone Metastasis - Other 0.718
No 19.0 (15.21–22.79)
Yes 19.0 (11.00–27.00)
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Predictive factors of survival after HCC diagnosis
Considering all patients included in this study (N= 211) the
median overall survival time from diagnosis of HCC was 19
months (CI 95%, 15.62–22.38) while the median survival from the
start of Sorafenib was 9 months (CI 95%, 7.44–10.56 months) and
median time to progression was 5 months (CI 95%: 3.70–6.30
months). The univariate analysis, reported in Table 5, demon-
strates that the median overall survival was significantly correlated
to Grading (p=0.019), Child score at diagnosis (p=0.001),
presence of bone metastasis localized to spine (p=0.018) and
absence of any locoregional treatment (p,0.001). At multivariate
analysis, absence of locoregional treatment (p,0.001; HR: 0.265),
Child score at diagnosis (p=0.049; HR: 1.572) and presence of
bone metastasis to spine (p=0.001; HR=2.281) were confirmed
and independently correlated with a shorter overall survival
(Table 5).
Skeletal outcomes and SREs in the overall population
The median number of SREs experienced by patients was one
(range 0–3). Median survival after development of the first SRE
was 8 months (CI 95% 7.17–8.20 months). The univariate
analysis, reported in Table 6, demonstrates that the median
survival after development of the first SRE was significantly
shorter according to the type of first SRE (2 months for spinal cord
compression, 3 months for surgery to bone, 4 months for
pathological fracture, 5 months for hypercalcemia and for
radiation to bone; CI 95%: 0.32–3.67, 0.00–7.80, 2.24–5.75,
0.00–10.13 and 3.79–6.20 months respectively; p=0.024) and in
patients that did not receive any locoregional treatment (p,0.001),
bisphosphonate therapy (p=0.001) and with presence of bone
metastasis localized to spine (p=0.027). At multivariate analysis,
locoregional treatment and presence of bone metastastasis
localizated to spine were confirmed and independently correlated
with a shorter survival after development of the first SRE
(p=0.030; HR: 4.709 and p,0.001; HR: 12.280, respectively)
(Table 6). The median time to first SRE after confirmed diagnosis
of bone metastasis was 3 months (CI 95%, 2.27–3.73 months),
indicative of the severity of bone metastasis in HCC. The median
time to second SRE was 6 months and to third SRE was 9 months.
At univariate analysis (Table 7), the median time to first SRE after
confirmed diagnosis of bone metastasis was significantly shorter
according to Child Score (p,0.001), ECOG PS (p= 0.014) and in
patients with presence of bone metastasis localized to Spine
(p=0.021) and in other site excluding hip, long bones and the
same spine (p=0.021). At multivariate analysis, only bone
metastasis localized in other site which are not spine, hip and
long bones were confirmed and independently correlated with a
shorter time to first SRE after confirmed diagnosis of bone
metastasis (p=0.025; HR: 0.570). All data described are reported
in Table 7.
Skeletal outcomes and SREs according to time of bone
metastases appearance
The entire population was divided in three subpopulations
(synchronous bone metastases, metachronous bone metastases and
patients with only bone metastases) and each subgroups was
characterised for the following parameters: clinical, pathological
and bone metastases characteristics, SREs and skeletal outcomes.
The three groups were homogeneous for age, gender, visceral
metastases, type, site and number of bone lesions and type and
number of SRE. Interestingly, median survival after bone
metastases diagnosis resulted the same (7 months) in the three
groups of patients, indicative of the poor prognosis strictly related
to the presence of bone disease in HCC patients.
Discussion
Bone is an uncommon site of metastasis in HCC, with the
incidence ranging from 3% to 20% [11–14]. Anyway bone
involvement in patients with HCC is increased in the last decades
probably due to the longer survival of HCC patients related to
recent progresses made both in the diagnosis and treatment of the
disease [14,15]. Some retrospective studies with a limited number
of patients have described the characteristics of bone metastasis
from HCC [11–16]. To our knowledge, this study is the recent
largest multicentre survey investigating the natural history of
metastatic bone disease in patients with HCC. Approximately less
than one third presented bone metastasis at the time of initial
HCC diagnosis, whereas the others developed bone metastasis
during disease progression. Interestingly, median survival after
Table 5. Cont.
VARIABLES
MEDIAN TIME
[MONTHS (95% C.I.)]
p VALUE
(univariate)
p VALUE
(multivariate)
HAZARD
RATIO (HR)
First SRE Type 0.742
Pathologica Fracture 21.0 (16.68–25.32)
Hypercalcemia 19.0 (11.3–26.70)
Spinal Cord Compression 24.0 (9.97–38.03)
Surgery to Bone 18.0 (0.00–38.53)
Radiation to Bone 18.0 (12.86–23.14)
Biphosphonate Treatment 0.529
No 18.0 (12.64–23.36)
Yes 19.0 (16.35–21.65)
doi:10.1371/journal.pone.0105268.t005
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Table 6. Predictive factors of survival after the development of the first SRE.
VARIABLES
MEDIAN TIME
[MONTHS- (95% C.I.)]
p VALUE
(univariate)
p VALUE
(multivariate)
HAZARD
RATIO (HR)
Age 0.872
,70 Years 2.0 (0.63–3.37)
.70 Years 2.0 (0.34–3.66)
SEX 0.799
Male 1.0 (0.00–2.21)
Female 3.0 (1.67–4.32)
Aetiology 0.339
HBV-related 0.0 (0.00–0.00)
HCV-related 3.0 (1.512 (4.49)
Alcohol-related cirrhosis 2.0 (0.93–3.07)
Other 0.0 (0.00–0.00)
Grading 0.847
G1 3.0 (0.06–5.94)
G2 2.0 (0.00–5.96)
G3 1.0 (0.00–2.16)
Locoregional Treatment 0.000 0.030 0.575
No 0.0 (0.00–0.00)
Yes 3.0 (1.91–4.10)
Type of locoregional Treatment 0.330
Surgery 4.0 (2.90–5.10)
Interventional Radiology 2.0 (0.51–3.50)
Type of interventional Radiology 0.089
RFA 3.0 (1.21–4.79)
TACE 2.0 (2.32–5.80)
PEI 1.0 (0.00–10.70)
CHILD Score
(at time of Bone Metastasis)
0.509
A 1.0 (0.00–3.49)
B 3.0 (2.26–3.74)
C 4.0 (2.06–5.95)
AFP (median value at diagnosis) 0.186
,43 ng\ml 3.0 (1.80–4.20)
.43 ng/ml 1.0 (0.70–3.10)
Visceral Metastasis 0.119
Yes 1.0 (0.00–1.94)
No 2.0 (1.06–2.95)
ECOG PS
(at time of Bone Metastasis)
0.115
0 1.0 (0.00–3.34)
1 3.0 (1.65–4.35)
2 2.0 (0.00–4.31)
3 0.0 (0.00–0.00)
Bone Lesion Type 0.362
Osteolytic 2.0 (0.44–3.57)
Ostroblastic 2.0 (0.88–3.12)
Mixed 2.0 (0.00–4.11)
Bone metastasis - Spine 0.027 0.000 2.049
No 3.0 (1.30–4.70)
Yes 1.0 (0.00–2.00)
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bone metastases diagnosis resulted the same in both groups (7
months). Moreover, these two populations of bone metastatic
HCC patients did not show any significant difference in terms of
clinical, pathological and bone metastases characteristics, SREs
and skeletal outcomes. The lack of differences could be indicative
of the poor prognosis associated with the presence of bone disease
in HCC patients. Among all the clinical and pathological
parameters predicting the appearance of metastasis, only the
Child Score resulted independently correlated early bone
progression. This is the first report that indicates the Child Score
not only as a predictor of overall survival, but also of a greater
tendency to bone metastatization and biological osteotropism of
HCC. The most common site (spine) and type (osteolytic) of bone
metastasis are consistent with previous smaller reports and were
confirmed in this study [14,16]. Moreover, we found in the
multivariate analysis that the localization of bone metastasis to
spine is correlated with a shorter survival after development of first
SRE and, in addition, a shorter overall survival from HCC
diagnosis. This is quite different from the analysis of other bone
metastasic hystotypes and from the previous reports in HCC [17].
Thus, we have found that the site of metastasis is correlated with
survival, whereas the number of bone lesions do not.
Prospective data on the efficacy of bisphosphonates in bone
metastatic HCC are lacking in literature [18]. This study revealed
also that the bisphosphonate treatment impact on survival from
the diagnosis of bone metastasis but, surprisingly, not on time to
first SRE. It is possible that this result may be influeced by a
selection bias exposed in the limitations of this study. Limitations
of this study include its retrospective design and inclusion of an
unselected heterogeneous cohort of patients with all types of
aetiologic variants of HCC, liver function variants (Child score) as
well as only approximately more than half of patients have been
treated with Sorafenib. However, the types of patients included in
this study represent the typical scenario of a real clinical practice.
Another limitation is the heterogeneity of standardized methods
used for detecting bone metastases, with each methodology having
its own limit of detection. In summary, the results presented in this
multicenter survey represent a significant improvement in the
understanding the natural history of skeletal disease in HCC
patients. In particular, we showed that the presence of bone
metastases should always be considered in patients with a worst
Child Score, even in the absence of clear symptoms, due to
associated greater biological osteotropism. Second, the site of bone
metastasis but not the number of the lesions is an important
prognostic factor of survival from first SRE and, surprisingly, of
overall survival. With impact on clinical practice, our results
showed also that the use of bisphosphonates has an impact on
survival from the diagnosis of bone metastasis in this population
and, even if the study was unpowered to demonstrate that,
bisphosphonates therapy should be considered.
The major limitation of this study is the absence of the control
group. In fact, this study was designed as a retrospective
observational study, aimed to describe only the natural history
of HCC patients with bone metastases.
Finally, we found a significantly longer median survival after
bone metastases diagnosis (7 months) compared to previous
reports [14,17]. This is extremely important since longer survival
means augmented risk of SRE e subsequent worsening in quality
of life (QOL).
Table 6. Cont.
VARIABLES
MEDIAN TIME
[MONTHS- (95% C.I.)]
p VALUE
(univariate)
p VALUE
(multivariate)
HAZARD
RATIO (HR)
Bone Metastasis - Long Bones 0.191
No 1.0 (0.00–2.16)
Yes 4.0 (2.73–5.27)
Bone Metastasis - Hip 0.382
No 2.0 (0.84–3.16)
Yes 2.0 (0.00–4.19)
Bone Metastasis - Other 0.154
No 3.0 (2.19–3.81)
Yes 0.0 (0.00–0.00)
First SRE Type 0.024 0.239 0.935
Pathologica Fracture 4.0 (2.24–5.76)
Hypercalcemia 5.0 (0.00–10.13)
Spinal Cord Compression 2.0 (0.33–3.67)
Surgery to Bone 3.0 (0.00–7.80)
Radiation to Bone 5.0 (3.80–6.20)
Biphosphonate Treatment 0.001 0.727 0.931
No 0.0 (0.00–0.00)
Yes 4.0 (2.99–5.02)
doi:10.1371/journal.pone.0105268.t006
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Table 7. Predictive factors of onset of first SRE.
VARIABLES
MEDIAN TIME
[MONTHS (95% C.I.)]
p VALUE
(univariate)
p VALUE
(multivariate)
HAZARD
RATIO (HR)
Age 0.670
,70 Years 8.0 (7.11–8.89)
.70 Years 7.0 (5.33–8.67)
Gender 0.403
Male 8.0 (6.70–9.30)
Female 8.0 (6.91–9.09)
Aetiology 0.095
HBV-related 8.0 (5.72–10.28)
HCV-related 8.0 (7.11–8.89)
Alcohol-related cirrhosis 7.0 (4.46–9.54)
Other 11.0 (6.23–15.77)
Grading 0.907
G1 7.0 (4.29–9.71)
G2 11.0 (4.78–17.22)
G3 9.0 (6.85–11.15)
Locoregional Treatment 0.239
No 10.0 (5.61–14.39)
Yes 7.0 (6.27–7.73)
Type of locoregional Treatment 0.717
Surgery 7.0 (5.63–8.37)
Interventional Radiology 8.0 (7.19–8.81)
Type of interventional Radiology 0.378
RFA 8.0 (6.07–9.94)
TACE 7.0 (6.10–7.90)
PEI 14.0 (6.27–21.74)
CHILD Score (At time of bone metastasis) 0.000 0.369 1.138
A 9.0 (6.24–11.76)
B 8.0 (6.94–9.07)
C 6.0 (4.96–7.04)
AFP (median value atdiagnosis) 0.297
,43 ng\ml 9.0 (6.78–11.22)
.43 ng/ml 7.0 (6.37–7.63)
Visceral Metastasis 0.073
Yes 7.0 (6.24–7.76)
No 12.0 (9.53–14.47)
ECOG PS (at time of Bone Metastasis) 0.014 0.297 1.133
0 12.0 (9.24–14.76)
1 8.0 (7.06–8.94)
2 7.0 (5.75–8.26)
3 7.0 (3.02–10.98)
Bone Lesion Type 0.895
Osteolytic 8.0 (7.04–8.96)
Ostroblastic 9.0 (5.88–12.12)
Mixed 8.0 (7.00–9.00)
Bone metastasis - Spine 0.021 0.767 1.062
No 10.0 (7.93–12.07)
Yes 7.0 (6.27–7.74)
Bone Metastasis - Long Bones 0.422
No 8.0 (7.11–8.89)
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